After disease progression on FOLFOX, the patient was enrolled in a PD1-directed immunotherapy combination trial, then received off-label treatment with the MEK inhibitor trametinib, and then received off-label treatment with the PARP inhibitor olaparib, but her cancer rapidly progressed on all of these treatments. Here, MAP2K7 is linked to cancer.